Inclusion Criteria:

          1. Able to understand and voluntarily sign the ICF and able to comply with the study
             visit schedule and the other protocol requirements.

          2. Patient (male or female) ≥18 years of age willing to agree to not father a
             child/become pregnant and comply with effective contraception criteria.

          3. Must have progressed following standard therapy, or for whom, in the opinion of the
             Investigator, no effective standard therapy exists, is tolerated or is appropriate.

          4. ECOG (Eastern cooperative oncology group) performance status ≤2

             Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):

          5. Patients must be screened for Hepatitis B virus and Hepatitis C virus

        Exclusion Criteria:

          1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations.
             (Exceptions are KRAS G12-mutant NSCLC's)

          2. History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          3. Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          4. Clinically significant cardiac disease.

          5. Active diarrhea or inflammatory bowel disease

          6. Insufficient bone marrow function

          7. Insufficient hepatic and renal function.

             Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):

          8. Patients with a known history of human immunodeficiency virus (HIV) seropositivity.

          9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use
             at the time of study entry.

         10. Patients who have undergone a bone marrow or solid organ transplant

         11. Patients with a history or presence of interstitial lung disease or interstitial
             pneumonitis

         12. Bullous and exfoliative skin disorders at screening of any grade

         13. Presence of clinically significant ophthalmological abnormalities that might increase
             the risk of corneal epithelial injury